Amphastar Pharmaceuticals (NASDAQ:AMPH) Earning Somewhat Favorable News Coverage, Analysis Shows
News coverage about Amphastar Pharmaceuticals (NASDAQ:AMPH) has trended somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Amphastar Pharmaceuticals earned a news sentiment score of 0.24 on Accern’s scale. Accern also assigned news stories about the company an impact score of 47.4553874115019 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news stories that may have impacted Accern Sentiment’s rankings:
- Amphastar Pharmaceuticals, Inc. (AMPH) Rating Reiterated by Jefferies Group LLC (americanbankingnews.com)
- $68.67 Million in Sales Expected for Amphastar Pharmaceuticals, Inc. (AMPH) This Quarter (americanbankingnews.com)
- Edited Transcript of AMPH earnings conference call or presentation 9-Aug-17 9:00pm GMT (finance.yahoo.com)
- Amphastar Pharmaceuticals, Inc. (AMPH) Posts Earnings Results, Beats Expectations By $0.05 EPS (americanbankingnews.com)
- Amphastar Pharmaceuticals (AMPH) to Repurchase $20.00 million in Stock (americanbankingnews.com)
AMPH has been the subject of several recent analyst reports. Jefferies Group LLC set a $21.00 price target on Amphastar Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, April 20th. Zacks Investment Research downgraded Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, May 16th. TheStreet upgraded Amphastar Pharmaceuticals from a “c” rating to a “b-” rating in a report on Monday, June 26th. Wells Fargo & Company restated a “buy” rating on shares of Amphastar Pharmaceuticals in a report on Saturday, July 22nd. Finally, BidaskClub downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, July 28th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $19.86.
Amphastar Pharmaceuticals (AMPH) traded down 2.49% on Friday, hitting $14.89. The stock had a trading volume of 246,952 shares. The stock has a market capitalization of $687.84 million, a price-to-earnings ratio of 193.38 and a beta of 1.65. Amphastar Pharmaceuticals has a 52 week low of $12.05 and a 52 week high of $21.75. The company has a 50-day moving average price of $17.25 and a 200-day moving average price of $15.91.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Wednesday, August 9th. The company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.05. Amphastar Pharmaceuticals had a return on equity of 2.42% and a net margin of 1.61%. The firm had revenue of $65.20 million for the quarter, compared to the consensus estimate of $63.40 million. During the same quarter in the previous year, the business earned $0.23 EPS. The company’s revenue was down 4.1% compared to the same quarter last year. Equities research analysts anticipate that Amphastar Pharmaceuticals will post $0.40 earnings per share for the current fiscal year.
Amphastar Pharmaceuticals declared that its Board of Directors has authorized a share repurchase program on Wednesday, August 9th that allows the company to repurchase $20.00 million in outstanding shares. This repurchase authorization allows the company to reacquire up to 2.8% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s leadership believes its shares are undervalued.
In other news, Director Jason B. Shandell sold 11,482 shares of the business’s stock in a transaction that occurred on Wednesday, May 31st. The stock was sold at an average price of $16.92, for a total value of $194,275.44. Following the transaction, the director now owns 241,342 shares in the company, valued at approximately $4,083,506.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Michael A. Zasloff sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $17.01, for a total value of $255,150.00. Following the completion of the transaction, the director now owns 47,411 shares in the company, valued at approximately $806,461.11. The disclosure for this sale can be found here. Insiders sold a total of 36,482 shares of company stock worth $620,125 in the last 90 days. Company insiders own 11.10% of the company’s stock.
WARNING: “Amphastar Pharmaceuticals (NASDAQ:AMPH) Earning Somewhat Favorable News Coverage, Analysis Shows” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/13/amphastar-pharmaceuticals-nasdaqamph-earning-somewhat-favorable-news-coverage-analysis-shows.html.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.